New ACOG Guidelines on Cervical Ripening

Critical Concerns About Misoprostol (Cytotec) Use

The latest ACOG Clinical Practice Guideline (#9, July 2025) strongly recommends misoprostol for cervical ripening, yet this drug remains FDA-unapproved for obstetric use and carries significant risks including uterine rupture, especially in patients with prior uterine surgery, strong uterine contractions, and fetal distress, especially when used without…